Financials in USD. Standardized financial statements.
A compact view of how TriSalus Life Sciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $45.15M | $29.43M | $18.51M | $12.40M | $8.40M | $0 |
| Revenue Growth? | +53.4% | +59.0% | +49.3% | +47.6% | 0.0% | 0.0% |
| Cost of Revenue? | $6.96M | $4.10M | $2.60M | $2.26M | $1.19M | $0 |
| Gross Profit? | $38.19M | $25.33M | $15.91M | $10.14M | $7.21M | $0 |
| Gross Margin? | +84.6% | +86.1% | +85.9% | +81.8% | +85.8% | 0.0% |
| Operating Expenses? | $65.13M | $61.49M | $70.38M | $46.58M | $31.24M | $108,493 |
| Operating Income? | -$26.95M | -$36.16M | -$54.48M | -$36.44M | -$24.03M | -$108,493 |
| EBITDA? | -$26.95M | -$36.16M | -$58.65M | -$46.76M | -$23.57M | -$711,386 |
| Income Before Tax | -$39.22M | -$30.04M | -$59.35M | -$47.18M | -$28.84M | -$711,389 |
| Income Tax Expense | $7,000 | $6,000 | $9,000 | $9,000 | $3,000 | $0 |
| Net Income? | -$39.23M | -$33.23M | -$59.36M | -$47.19M | -$28.84M | -$31.83M |
| EPS? | $-1.84 | $-1.25 | $-2.23 | $-1.59 | $-0.92 | $-0.02 |
| Diluted EPS? | $-1.84 | $-1.25 | $-2.23 | $-1.59 | $-0.92 | $-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality